This section contains news items that were not issued as a press release.
- Thursday, 5 January 2012
- Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept’s product candidate AZD1446 as a treatment for Alzheimer’s disease.
- Wednesday, 21 December 2011
- Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma Dynavax Technologies Corporation announced today they will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work performed by Dynavax under the recently amended collaboration agreement with AstraZeneca for the clinical development of AZD 1419. Development expenses will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6 million to begin the studies.
- Wednesday, 21 December 2011
- AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy
- Wednesday, 21 December 2011
- AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
- Tuesday, 20 December 2011
- AstraZeneca updates on olaparib and TC-5214 development programmes AstraZeneca today announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point.
- Thursday, 15 December 2011
- Enlight Biosciences forms new partnerships with AstraZeneca and Novo Nordisk Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk. As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to proactively address critical unmet industry needs.
- Tuesday, 13 December 2011
- AstraZeneca out-licenses imaging agent for amyloid detection to aid diagnosis of Alzheimer’s disease to Neoprobe AstraZeneca today announced it has out-licensed AZD4694, its late-stage radiopharmaceutical imaging candidate, to Neoprobe Corporation. AZD4694 is a Flourine-18 labeled radiotracer discovered by AstraZeneca to support development of potential treatments for Alzheimer´s disease.
- Wednesday, 7 December 2011
- Groundbreaking scientific collaboration gives UK academia access to selected AstraZeneca compounds Following a unique landmark agreement between AstraZeneca and the UK Medical Research Council (MRC) a wide range of compounds will be made available to UK medical researchers next year.
- Monday, 28 November 2011
- AstraZeneca Excellence in Chemistry Awards 2011 At AstraZeneca, we recognize that advances in medicine rely on innovations in chemistry. To reward outstanding contributions to the art of organic chemistry, we are introducing a global awards program where we will present two AZ Young Investigator Awards in each region (North America, Europe and Asia) annually and one global AZ Distinguished Career Award every other year (starting 2012). This program builds on the legacy of our different existing national or regional awards programs, where some of them have been in place for over 25 years.
- Wednesday, 9 November 2011
- New six-way agreement among Pharmas and NGOs will speed development of TB drug combinations AstraZeneca is proud to join Bayer, Sanofi and Tibotec in partnership with TB Alliance and the World Health Organization in a six-way alliance through which the companies will share information about the tuberculosis (TB) compounds in their pipelines to quickly identify and collaborate to develop the most promising TB drug regimen, regardless of sponsor. By facilitating a more collaborative approach to TB drug development, the partnership aims to dramatically speed the development of shorter, safer, and more effective multi-drug treatments which are urgently needed to control the global TB pandemic.